Our metabonomic, transcriptomic, and molecular biology studies demonstrated that Chi, in part, diminished the Warburg effect by reducing glucose and lactate production in imatinib-resistant CML cells through the PPARγ/mTOR/PKM2 pathway. The gene discussed is MTOR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.